WhatisTirzepatideandwheretobuyTirzepatide?
-ByPolypeptide.ltd TirzepatidePeptideStructure
Authoritativesource：PubChem
1.WhatisTirzepatide?
Tirzepatideisasyntheticderivativethatcombinesthefunctionalitiesofgastricinhibitory polypeptide(GIP)andglucagon-likepeptide-1(GLP-1).Thisuniquecombinationenables Tirzepatidetoeffectivelylowerbloodglucoselevels,improveinsulinsensitivity,promotefeelings ofsatiety,andfacilitateweightloss.
Tirzepatide(Tirzepatidebrandname:Mounjaro)isinitiallyusedfortype2diabetestolowerblood sugar.Diabetesisalong-termconditionwhenyourbloodsugars(HbA1c)becometoohighbecause yourbodydoesnotproduceoruseinsulinnormallyTirzepatideworkstodecreasebloodsugar levelsbyincreasinginsulinproductionandalsoloweringtheamountofsugarthelivermakes.It alsoslowstherateatwhichfoodpassesthroughyourbody,whichmakesyoufeelfulllonger,and thismaybeoneofthewaysitmayhelpwithweightlossTirzepatidehasalsodemonstratedthe
abilitytoprotectthecardiovascularsystemandactasapotentagentforweightloss..
2.MechanismofactionofTirzepatide?
•Dualglucose-dependentinsulinotropicpolypeptide(GIP)andglucagon-likepeptide-1(GLP-1) receptoragonist
•GIPisanincretinhormonethatinducesinsulinsecretioninresponsetoameal(primarilyby hyperosmolarityofglucoseintheduodenum)tofacilitatethemetabolismofcarbohydrates,fats,and proteins
•GLP-1receptoragonistsincreaseinsulinsecretioninthepresenceofelevatedbloodglucose, suppressglucagonpostprandially,delaygastricemptyingtodecreasepostprandialglucose,and decreaseglucagonsecretion
•Pharmacodynamiceffectsobservedincludelowerfastingandpostprandialglucoseconcentration, decreasedfoodintake,andreducedbodyweight.
3.WhatarethebenefitsofTirzepatide?
❶ImprovedGlycemicControl.Tirzepatidehelpsregulatebloodsugarlevelsinindividualswith type2diabetes.Itworksbystimulatingthereleaseofinsulinfrompancreaticbetacellsand inhibitingthereleaseofglucagon,whichhelpstoreducetheamountofglucoseproducedbythe liverByincreasinginsulinsensitivityandreducingglucoseproduction,Tirzepatidecanleadto improvedglycemiccontrolandlowerHbA1clevels.
❷WeightLoss.Tirzepatidehasshownpromiseasamedicationthatcancontributetoweightloss. ItactsontheGLP-1receptor,whichhelpstoslowdowngastricemptyingandpromotefeelingsof fullnessandsatiety.Theseeffectscanleadtoareducedcaloricintakeandpotentialweightloss. ClinicaltrialshavedemonstratedsignificantweightlossinindividualsusingTirzepatidecompared tothoseusingaplaceboorotherdiabetesmedications
❸CardiovascularBenefits.Tirzepatidehasexhibitedpotentialcardiovascularbenefitsbeyondits effectsonbloodsugarcontrol.Clinicaltrialshaveshownapotentialreductionintheriskofmajor adversecardiovascularevents,includingheartattacks,strokes,andcardiovascular-relateddeath. ThesefindingssuggestthatTirzepatidemayhaveadditionalprotectiveeffectsonthecardiovascular system,makingitavaluableoptionforindividualswithtype2diabetesatriskofcardiovascular complications
❹CombinationTherapy.Tirzepatidecanbeusedasamonotherapyorincombinationwithother diabetesmedications,suchasmetforminorSGLT2inhibitorsThisflexibilityallowshealthcare providerstotailortreatmentplanstothespecificneedsofeachpatient.Combinationtherapywith
Tirzepatidecanprovidecomprehensiveglycemiccontrolbyaddressingdifferentaspectsofglucose regulation.
❺SingleWeeklyInjection.OneoftheadvantagesofTirzepatideisitsonce-weeklydosing regimenUnlikesomeotherdiabetesmedicationsthatrequiredailydosing,Tirzepatidecanbe administeredonceaweek,providingconvenienceandpotentiallyimprovingtreatmentadherence Thissimplifieddosingschedulecanmakeiteasierforindividualstoincorporatethemedicationinto theirroutine
4.Tirzepatideforweightloss
Tirzepatide'spotentialforweightlosscanbedescribedinlayeredpoints:
❶DualReceptorActivation.AsadualGIPandGLP-1receptoragonist,Tirzepatideactivatestwo importantreceptorsinvolvedinglucoseregulationandappetitecontrolThisdualactionprovidesa comprehensiveapproachtoweightmanagement.
❷SlowingGastricEmptying.ByactivatingtheGLP-1receptor,Tirzepatideslowsdownthe emptyingofthestomach.Thisleadstoaprolongedfeelingoffullnessandreducedappetite,asfood staysinthestomachforalongertimeThiseffectcanhelpindividualsconsumefewercaloriesand contributetoweightloss
❸AppetiteRegulation.ActivationoftheGLP-1receptoralsoaffectsthebrain'sappetitecontrol centers,leadingtoadecreaseinhungerandfoodcravings.Thiscanhelpindividualsmakehealthier dietarychoicesandresistovereating,supportingweightmanagementefforts
❺EnhancedInsulinSensitivity.Tirzepatide'simpactontheGIPreceptorimprovesinsulin sensitivityThismeansthatthebodycanutilizeglucosemoreeffectively,reducingtheneedfor excessinsulinsecretion.Improvedinsulinsensitivitymayhelpdecreasefatstorageandcontribute toweightloss
❻ReductioninLiverGlucoseProduction.Tirzepatide'sactionontheGIPreceptoralsodecreases theproductionofglucosebytheliverThishelpstofurtherregulatebloodsugarlevelsandprevent excessiveglucoserelease,whichcancontributetoweightlossbyreducingtheavailabilityofstored energy
❼ClinicalTrialEvidence.Clinicaltrialshavedemonstratedsignificantweightlossinindividuals
usingTirzepatidecomparedtothosereceivingaplaceboorotherdiabetesmedications.Thesetrials provideevidenceforthepotentialefficacyofTirzepatideinpromotingweightreduction.
❽FDAApproval.Itisimportanttonotethat,asofmyknowledgecutoffinSeptember2021, TirzepatidehadnotreceivedFDAapprovalspecificallyforweightlossTherefore,usingTirzepatide forweightlossshouldbediscussedwithahealthcareprofessional,whocanprovideguidancebased onthelatestinformationandindividualcircumstances.
Remember,whileTirzepatideshowspromiseforweightloss,itsuseshouldbeunderthesupervision andguidanceofahealthcareprofessionaltoensuresafetyandeffectivenessinachievingweight managementgoals.
5.SideeffectsofTirzepatide
TirzepatidemaycausesideeffectsIfanyofthesesymptomsaresevereordonotgoaway,you shouldconsultyourdoctor:
•vomiting
•nausea
•diarrhea
•decreasedappetite
•constipation
•upsetstomach
Somesideeffectscanbeserious.Callyourdoctorrightawayandstoptakingthismedicationifyou haveanyofthefollowingsymptomsoranyofthosementionedintheImportantInformation section:
•stomachpainthatwillnotgoaway(andmayradiatetotheback)withorwithoutvomiting
•Tirzepatidemayresultinhypoglycemia,orlowbloodsugar
Lowbloodsugarsymptomsandwarningindicationsmightincludeheadache,jitteriness, perspiration,slurredspeech,dizzinessorlightheadedness,anxiety,irritability,ormoodswings, hunger,disorientationorsleepiness,shakiness,weakness,andheadacheOtheradverseeffectsfrom thismedicationarepossibleIfyouhaveanyoddissueswhileusingthisdrug,seeamedical practitionerrightaway.
6.Tirzepatidevs.Semaglutide
Tirzepatideandsemaglutidearebothmedicationsusedforthetreatmentoftype2diabetes,butthey differinseveralaspects:
❶MechanismofAction.TirzepatideisadualGIPandGLP-1receptoragonist,meaningit activatesboththegastricinhibitorypolypeptide(GIP)receptorandtheglucagon-likepeptide-1 (GLP-1)receptor.Ontheotherhand,semaglutideisaGLP-1receptoragonist,whichmeansit selectivelyactivatestheGLP-1receptor
❷DosageFrequency.Tirzepatideisadministeredonceweekly,whilesemaglutideisavailablein differentformulationswithvaryingdosingfrequencies,includingonce-dailyandonce-weekly options.
❸Efficacy.Clinicaltrialshaveshownthatbothtirzepatideandsemaglutidecaneffectivelylower bloodsugarlevelsandimproveglycemiccontrolinindividualswithtype2diabetesAdditionally, bothmedicationshavedemonstratedpotentialforweightlossasanadditionalbenefit
❹WeightLossEffects.Bothtirzepatideandsemaglutidehaveshownefficacyinpromoting weightlossinclinicaltrials.However,it'simportanttonotethatasofmyknowledgecutoffin September2021,semaglutidehasreceivedFDAapprovalasaweightlossmedicationina higher-doseformulationspecificallyforchronicweightmanagement,whiletirzepatidehadnotyet receivedsuchapproval.
❺SideEffects.Thesideeffectsoftirzepatideandsemaglutidecanbesimilarandmayinclude gastrointestinalsymptomssuchasnausea,vomiting,anddiarrheaHowever,thespecificsideeffects andtheirincidencecanvarybetweenindividualsandshouldbediscussedwithahealthcare professional.
❻FDAApproval.AsofmyknowledgecutoffinSeptember2021,bothtirzepatideandsemaglutide havereceivedFDAapprovalforthetreatmentoftype2diabetesSemaglutidehasalsoreceived FDAapprovalforchronicweightmanagementinahigher-doseformulation.
7.DosageofTirzepatide?
Youshouldcarefullyreadtheinstructionsonyourprescriptionlabelandaskyourpharmacistor
doctortoclarifyanyinformationyouareunsureof.It'scrucialtotakethismedicationexactlyas recommended.Nevertakeitinlargerorlessamountsormorefrequentlythandirectedbyyour doctor
Tirzepatidecomesasasolution(liquid)inapre-filledpenthatisinjectedundertheskin (subcutaneously)Itisusuallygiven：
•onceaweek
•canbegivenwithorwithoutmeals,atanytimeoftheday.
•maybeinjectedintothethigh,abdomen,orupperarm
•Youshouldrotateinjectionsiteswitheachdose.
•Yourdoctorwillprobablystartyouonalowdosewhichmaybegraduallyincreased,butnot morethanonceevery4weeks
Tirozepatideandinsulincanbothbeadministeredinthesameplace,buttheyshouldn'tbegiven adjacenttooneanother.Additionally,insulinandtirzepatidshouldnotbeblendedinoneinjection; theyshouldbeadministeredseparately
Althoughitdoesnotcuretype2diabetes,tirzepatidemanagesitBeforeyougetthefullbenefitsof thismedication,itmighttakeuptofourweeksTakethismedicationevenifyoufeelOKWithout consultingyourdoctor,donotdiscontinueusingthismedication.
8.WhatshouldIdoifImissadose?
TakethemissingTirzepatidedosageassoonasyourecallit,aslongasitislessthanfourdays followingthemisseddose.Themisseddosageshouldnotbetaken,andyourusualdosingplan shouldcontinueifithasbeenmorethan4dayssinceyourlastdoseDonotprovidetwodosesthree daysapart.
9.StoragerequirementsforTirzepatide?
TirzepatideundertheMounjaronameshouldbekeptinthefridgebetween36°Fand46°F(2°Cand 8°C).Toprotectitfromlight,keepitintheoriginalboxuntilusage.Ifrequired,single-dosepens canbekeptatroomtemperatureforupto21days.Onlystoreyourmedicineasrecommended.
Makesureyouareawareoftherightpharmaceuticalstoragetechniques
10.WheretobuyTirzepatidefrom?
Polypeptide.ltdisthereliablemanufacturerofTirzepatide,producesTirzepatidestrictlyaccordingto cGMPstandards,andisequippedwithHPLC,GC,andotheranalyticalinstrumentsTestscanbe doneonIR,GC/MS,LC/MS,and400NMRattheSIOCthroughacontract.Customsynthesized peptideIthasafullyautomaticinjectionfillinglinewithmultiplefillingmodulesandabuilt-in freezedryer,whichcanfillvials,syringes,andcartridgesofvarioussizesandcanalsoproduce freeze-driedpowder.QAoperationshavebeeninplaceforseveralyearstoensurethatproductsat ourcompanyarepreparedresponsiblyandinaccordancewithISO9001standards
IfyouarelookingforTirzepatideforsale,areliableandreputableTirzepatide manufacturer/supplier/factory/traderisagoodchoice.polypeptide.ltdisaone-stopshopforreliable Tirzepatidepeptidemanufacturers,suppliers,andwholesalers.WhenyouorderfromPolypeptide Ltd,youcanrestassuredthateachorderofTirzepatide,whetherretailorwholesaleTirzepatide, willbeshippedoutontimeanddeliveredsafely.PolypeptideLtd.canshipTirzepatidetoanywhere intheworld,includingtheUSA,Canada,Mexico,Europe,andAustraliaShipdirectlytoyour addresswithsafeandsecurelocaldeliveryAdditionally,Polypeptideltdcanprovideacompetitive priceofTirzepatideonthemarketforthoselookingtobuyTirzepatidepowderorfreeze-dried powder
11.HowtobuyTirzepatidefromPolypetide.ltd?
Polypeptide.ltdisthebestTirzepatidemanufacturerinChinaandourfactoryproduceshighquality Tirzepatideinterm,wewelcomemanyrequestersandbuyersofpureTirzepatidetocontactus!
IndividualusersshouldavoidbuyingbulkTirzepatideTheadvantagesofwholesaleTirzepatidebulk powderfrompolypeptideltdinclude:
❶Factoryproductiononalargescale,consistentsupply,ashortdeliverycycle,andhighprice competitiveness;
❷Provideaqualityassurancereportforthecorrespondingbatchofqualitytestreport;
❸Professionallogisticscustomizationsolutions,on-timedelivery;
❹Paymentmethodsthatarediverse,suchasTTandvirtualcurrency;
❺High-qualitypre-salesandafter-salesservice,followedbyproductandorderdetailsconsultation.
12.HowtogetthequickquoteofTirzepatideonline?
VisitprofessionalTirzepatidesupplierinChina-polypeptide.ltdwebsite,choosetheTirzepatideyou want,andleaveyourcontactandmessageonpolypeptideltdwebsite,thensubmitpolypeptideltd, thecustomerservicewillreplyyouin12hoursoncereceivedyourmessage,thentalkindetails aboutpureTirzepatide
13.Doespolypeptide.ltdsupportthefreesampleofTirzepatide powder?
Itdepends,differentproductswithdifferentpolicy,pleasecheckitwithourcustomerservice.Most ofproductscanbeacceptedforfreesampleWelcomeourclientstestourwhitepureTirzepatideat anytime!
Referencecitations
[1]AhangarpourM,KavianiniaI,HarrisPW,BrimbleMA(January2021)"Photo-inducedradical thiol-enechemistry:aversatiletoolboxforpeptide-baseddrugdesign"ChemicalSocietyReviews Royal Society of Chemistry. 50 (2): 898–944doi:101039/d0cs00354aPMID33404559S2CID230783854
[2]"AdvancingHealthThroughInnovation:NewDrugTherapyApprovals2022".U.S.Foodand DrugAdministration(FDA)10January2023Archivedfromtheoriginalon21January2023 Retrieved22January2023.Thisarticleincorporatestextfromthissource,whichisinthepublic domain
[3]Jumpupto:abcdefghijkl"DrugTrialsSnapshots:Mounjaro"USFoodandDrug Administration(FDA)13June2023Retrieved14June2023Thisarticleincorporatestextfrom thissource,whichisinthepublicdomain.
[4]DuttaD,SuranaV,SinglaR,AggarwalS,SharmaM(November–December2021)."Efficacy andsafetyofnoveltwincretintirzepatideadualGIPandGLP-1receptoragonistinthemanagement oftype-2diabetes:ACochranemeta-analysis"IndianJournalofEndocrinologyand
Metabolism.25(6):475–489.doi:10.4103/ijem.ijem42321.PMC8959203.PMID35355921.
[5]JastreboffAM,AronneLJ,AhmadNN,WhartonS,ConneryL,AlvesB,etal(4June 2022)."TirzepatideOnceWeeklyfortheTreatmentofObesity".NEJM.387(3): 205–216doi:101056/NEJMoa2206038PMID35658024S2CID249385412Archivedfromthe originalon5June2022Retrieved6June2022
[6]"Lilly:Phase3TirzepatideResultsShowSuperiorA1CAndBodyWeightReductionsInType 2Diabetes".BusinessInsider.RTTNews.19October2021.Archivedfromtheoriginalon28 October2021Retrieved28October2021
[7]Kellaher,Colin(28April2022)."EliLilly'sTirzepatideMeetsMainEndpointsinPhase3 ObesityStudy"MarketWatchDowJonesNewswiresArchivedfromtheoriginalon29April2022 Retrieved29April2022.
[8]FríasJP,DaviesMJ,RosenstockJ,PérezManghiFC,FernándezLandóL,BergmanBK,etal (August2021)."TirzepatideversusSemaglutideOnceWeeklyinPatientswithType2 Diabetes"TheNewEnglandJournalofMedicine385(6): 503–515.doi:10.1056/NEJMoa2107519.PMID34170647.S2CID235635529.
[9]Dee,JaneE.(6June2022)."MoreThan20%WeightReductioninIndividualsWith Obesity".YaleDepartmentofInternalMedicine.Archivedfromtheoriginalon10June2022. Retrieved12June2022
[10]Davis,Nicola(5June2022)"Diabetesdrugleadstonotableweightlossinpeoplewithobesity –study".TheGuardian.Archivedfromtheoriginalon11June2022.Retrieved12June2022.
[11]WorldHealthOrganization(2019)"Internationalnonproprietarynamesforpharmaceutical substances(INN):recommendedINN:list81".WHODrugInformation.33(1).hdl:10665/330896.
[12]Jumpupto:abc"MounjaroEPAR".EuropeanMedicinesAgency(EMA).18July 2022.Archivedfromtheoriginalon12December2022.Retrieved2January2023.Textwascopied fromthissourcewhichiscopyrightEuropeanMedicinesAgencyReproductionisauthorized providedthesourceisacknowledged.
[13]ForzanoI,VarzidehF,AvvisatoR,JankauskasSS,MoneP,SantulliG(November 2022)."Tirzepatide:ASystematicUpdate".IntJMol Sci23(23)doi:103390/ijms232314631PMC9741068PMID36498958
https://www.polypeptide.ltd/
[14]"Mounjaro:PendingECdecision".EuropeanMedicinesAgency.22July2022.Archivedfrom theoriginalon28July2022.Retrieved30July2022.Textwascopiedfromthissourcewhichis copyrightEuropeanMedicinesAgencyReproductionisauthorizedprovidedthesourceis acknowledged.
[15]"MounjaroProductinformation"UnionRegisterofmedicinalproductsArchivedfromthe originalon8February2023.Retrieved3March2023.
[16]"DrugandHealthProductSubmissionsUnderReview(SUR):Newdrugsubmissions completed"HealthCanada10March2021Archivedfromtheoriginalon5January2023 Retrieved5January2023.
[17]Jumpupto:abMinT,BainSC(January2021)"TheRoleofTirzepatide,DualGIPandGLP-1 ReceptorAgonist,intheManagementofType2Diabetes:TheSURPASSClinicalTrials".Diabetes Therapy12(1):143–157doi:101007/s13300-020-00981-0PMC7843845PMID33325008